Ticker Council Try it free

Stocks

CRBU (Caribou Biosciences, Inc.): what 12 AI analysts think

The Council's combined lean on CRBU, from everyone's recent runs on Ticker Council.

Updated November 17, 2026 · Totals only, never one person's run

The Council's lean

Next week
Leaning up, 54% chance of rising
From 2 calls in the last 3 days
Next 3 months
Leaning up, 53% chance of rising
From 2 calls in the last 14 days
Next year
Barely up, 50% chance of rising
From 2 calls in the last 30 days

Across recent runs, the Council is leaning up for next week (54% chance of rising, 2 calls); leaning up for the next 3 months (53% chance of rising, 2 calls); barely up for the next year (50% chance of rising, 2 calls).

How the twelve seats split (next 3 months)

Each seat reads one kind of data. This is how each one leaned across those same calls.

SeatLeaned
Price Chart2 up
Financials2 down
Analyst Targets2 down
Earnings Estimates2 up
Insider Trades2 even
Congress Trades2 even
News2 down
SEC Filings2 up
Institutional Holdings2 up
Options Market2 up
Economy2 even
Related Markets2 up
Track Recordno read
What It Holdsno read
Fund Flowsno read
Fund Checkno read
Market Backdropno read
Crypto Marketno read
Market Moodno read
Futures Marketno read
Options Marketno read
ETF Flowsno read
Stablecoin Supplyno read
On-Chainno read
Coin Checkno read

Every call is saved and scored later against what the price did: how calls are scored.

Questions

What do AI analysts think of CRBU (Caribou Biosciences, Inc.)?

Across 6 recent calls, Ticker Council's twelve AI analysts lean leaning up on CRBU for the next 3 months (53% chance of rising). Each seat reads one kind of data, they debate, and every call is scored afterwards. Not financial advice.

Is CRBU a buy?

Ticker Council doesn't say buy or sell. It shows which way the evidence leans and how sure the Council is. Right now: leaning up for the next 3 months (53% chance of rising). Use it as a second opinion and decide for yourself. Not financial advice.

Not financial advice. These are AI analysts' leans, not instructions to buy or sell, and they can be wrong.